EurekAlert! -
12 Nov 2016 07:00
(Mayo Clinic) A Mayo Clinic study is shedding light on why some rheumatoid arthritis patients respond poorly when treated with tumor necrosis factor inhibitors, part of a class of drugs called biologics.
Share this Article